The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Status of psychotropic drug blood level assays and other biochemical measurements in clinical practice

Published Online:https://doi.org/10.1176/ajp.136.9.1177

Assays of drug levels in blood and of other biochemical characteristics of psychiatric patients are being proposed for clinical application, although their utility in practice remains uncertain. Exceptions are the assay of blood levels of anticonvulsants and of lithium ion. Assays of antidepressant drugs may be especially helpful in the evaluation of unexpected responses or in the avoidance of unwanted toxic effects and promise to permit more efficient predictions of individual requirements. Assays of platelet MAO activity or urinary MHPG excretion remain clinically less useful. Attempts to correlate blood levels of antipsychotic agents with clinical effects have been disappointing, although newer assay methods may prove more useful.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.